NASDAQ:ARDS Aridis Pharmaceuticals (ARDS) Stock Price, News & Analysis $0.0001 0.00 (0.00%) As of 10/9/2026 11:15 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC Filings About Aridis Pharmaceuticals Stock (NASDAQ:ARDS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Aridis Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.0001▼$0.000150-Day Range N/A52-Week Range$0.00▼$0.05Volume233 shsAverage Volume15,782 shsMarket Capitalization$5.33 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aridis Pharmaceuticals, Inc. was a clinical-stage biopharmaceutical company focused on developing antibody-based therapies for serious infectious diseases. The company’s approach centered on fully human monoclonal antibodies designed to target specific bacterial pathogens and their disease-causing mechanisms, with the goal of providing alternatives or complements to traditional antibiotics. Aridis’ principal development programs included AR-301, also known as suvratoxumab, an investigational monoclonal antibody directed against Pseudomonas aeruginosa alpha toxin. The program was evaluated for the treatment of hospital-acquired and ventilator-associated pneumonia caused by Pseudomonas aeruginosa. The company also pursued additional antibody programs aimed at other bacterial infections, including candidates targeting pathogens associated with serious hospital and respiratory infections. Founded in 2003 and based in San Jose, California, Aridis conducted its research and clinical development activities primarily through collaborations and clinical studies involving patients in the United States and other regions. The company was led by founder and Chief Executive Officer Vu Truong, Ph.D. Aridis was a development-stage company, and its programs remained investigational rather than commercially approved products.AI Generated. May Contain Errors. Read More Receive ARDS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aridis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARDS Stock News HeadlinesAridis Pharmaceuticals, Inc. (ARDS) - Yahoo FinanceJuly 11, 2025 | finance.yahoo.comAridis Provides Corporate UpdateDecember 20, 2024 | globenewswire.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.October 11 at 1:00 AM | Stansberry Research (Ad)Horizon Tech Finance (NASDAQ:HRZN) Stock Quotes, Forecast and News SummaryOctober 11, 2024 | benzinga.comGenor Biopharma Holdings Limited (67N0.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comBreathing easier: Nature-inspired treatments could relieve acute respiratory distressAugust 3, 2024 | msn.comAridis Provides Corporate UpdateJune 24, 2024 | globenewswire.comIrish Cup: Institute's quarter-final place confirmed as IFA rejects Ards protestFebruary 10, 2024 | bbc.co.ukSee More Headlines ARDS Stock Analysis - Frequently Asked Questions How have ARDS shares performed this year? Aridis Pharmaceuticals' stock was trading at $0.0002 at the beginning of 2026. Since then, ARDS stock has decreased by 50.0% and is now trading at $0.0001. How were Aridis Pharmaceuticals' earnings last quarter? Aridis Pharmaceuticals, Inc. (NASDAQ:ARDS) posted its quarterly earnings data on Wednesday, November, 10th. The company reported ($1.94) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by $1.43. The company earned $0.52 million during the quarter. When did Aridis Pharmaceuticals IPO? Aridis Pharmaceuticals (ARDS) raised $28 million in an initial public offering on Tuesday, August 14th 2018. The company issued 2,000,000 shares at a price of $13.00-$15.00 per share. Cantor acted as the underwriter for the IPO and Maxim Group and Northland Capital Markets were co-managers. How do I buy shares of Aridis Pharmaceuticals? Shares of ARDS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aridis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aridis Pharmaceuticals investors own include VBI Vaccines (VBIV), Cidara Therapeutics (CDTX), Dare Bioscience (DARE), BioCardia (BCDA), Moleculin Biotech (MBRX), SCYNEXIS (SCYX) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings11/10/2021Today10/11/2026Next Earnings (Estimated)11/02/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ARDS CIK1614067 Webwww.aridispharma.com Phone(408) 385-1742Fax408-960-3822Employees37Year Founded2003Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares53,321,000Free Float50,388,000Market Cap$5.33 thousand OptionableNot Optionable Beta47.61 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:ARDS) was last updated on 10/11/2026 by MarketBeat.com Staff. From Our PartnersTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aridis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aridis Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARDS Stock Alerts